Skip to content
Products & Services · Total revenues

Total Rare — Total revenues

Alnylam Pharmaceuticals Total Rare — Total revenues decreased by 7.9% to $125.72M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.3%, from $109.06M to $125.72M. Over 2 years (FY 2023 to FY 2025), Total Rare — Total revenues shows an upward trend with a 23.3% CAGR.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
Metric ID: alny_segment_total_rare_total_revenues

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$82.27M$82.27M$82.27M$82.27M$100.71M$102.74M$111.26M$108.22M$109.06M$127.72M$126.7M$136.44M$125.72M
QoQ Change+0.0%+0.0%+0.0%+22.4%+2.0%+8.3%-2.7%+0.8%+17.1%-0.8%+7.7%-7.9%
YoY Change+22.4%+24.9%+35.2%+31.5%+8.3%+24.3%+13.9%+26.1%+15.3%
Range$82.27M$136.44M
CAGR+15.2%
Avg YoY Growth+22.4%
Median YoY Growth+24.3%

Frequently Asked Questions

What is Alnylam Pharmaceuticals's total rare — total revenues?
Alnylam Pharmaceuticals (ALNY) reported total rare — total revenues of $125.72M in Q1 2026.
How has Alnylam Pharmaceuticals's total rare — total revenues changed year-over-year?
Alnylam Pharmaceuticals's total rare — total revenues increased by 15.3% year-over-year, from $109.06M to $125.72M.
What is the long-term trend for Alnylam Pharmaceuticals's total rare — total revenues?
Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's total rare — total revenues has grown at a 23.3% compound annual growth rate (CAGR), from $329.09M to $499.92M.